D-Wave Quantum: Lawsuits Challenge the Record Orders While a Korean Partnership Points to Industry

Two narratives are running in parallel at D-Wave Quantum, and investors would do well not to confuse them. On one side, a fresh partnership with LG CNS and a prize won by a customer's research suggest the technology is moving closer to real-world use. On the other, securities litigation is questioning whether the company's celebrated order intake reflects genuine demand at all.

The stock slipped 2.0% in the latest session, having already come under pressure on Wednesday. According to media reports, the weakness stemmed from a sector-wide selloff in quantum names, profit-taking after an earlier rally and caution ahead of the Federal Reserve's rate decision. No company-specific negative catalyst was cited. That distinction matters: a broad mood shift says little about whether any single technology will translate into revenue.

A Memorandum, Not an Order

The agreement with LG CNS, signed Wednesday at Qubits Asia in Seoul, is a legally non-binding letter of intent. The two companies plan to combine D-Wave's annealing quantum computing with LG CNS's optimization and systems-integration expertise, aiming to move applications beyond proof-of-concept work into production use. Target customers span manufacturing, telecommunications, financial services and retail. No contract value was disclosed, and no binding customer order has been placed.

LG CNS brings roughly 50 optimization specialists and more than 200 optimization projects to the table. That experience could help push applications past isolated tests — but it guarantees neither an order nor any particular revenue contribution for D-Wave. The potential value lies in the intended transition from feasibility studies to industrial deployment. Should that handover succeed, D-Wave would have a better case for the commercial viability of its technology.

A Prize That Went Elsewhere

The same day brought word that customer Shionogi won the quality-of-life category of the NEDO Challenge for its research into quantum-assisted drug discovery. The ¥40 million prize supports Shionogi's further work. The awarded project included a peer-reviewed study integrating D-Wave's annealing technology into a generative AI model for molecular design — a concrete research link, to be sure. But the prize went to the customer, not to D-Wave, so no corresponding inflow of funds can be inferred.

Both developments fit a broader pattern: the path from promising technology to commercial use runs through several stages. Research successes can make applications more plausible; partnerships can ease access to customers. Neither should be dressed up in language that implies revenue already booked.

The Litigation's Core Claim

The more serious counterargument concerns the quality of demand rather than the timing of a single project. Rosen Law points to a complaint alleging that the order intake described as a record in 2026 consisted largely of two contracts already signed before the relevant purchase period. On that account, the figures would not demonstrate new or expanded commercial use. These are allegations, not established facts — but they flag a material risk: headline order numbers would carry less weight if they did not signal broader demand.

Per the complaint described by Kaplan Fox, D-Wave generated revenue of $3.08 million in the second quarter of 2026, compared with $3.1 million in the year-earlier quarter. Analyst expectations cited in the suit ranged between $4.03 million and $4.08 million. That gap explains why partnership announcements alone cannot settle the revenue question.

The filing further suggests D-Wave may struggle to convert its systems-sales pipeline into new orders, with system deliveries and related revenue possibly slipping into the fourth quarter of 2026 and into 2027. Should that risk scenario materialize, even the LG CNS tie-up would do little to dispel the economic uncertainty at first. Additional projects might broaden the application outlook, but without binding execution it would remain unclear when revenue actually arrives.

What Would Change the Picture

Binding orders, transparent delivery terms or identifiable revenue contributions would recast the partnership in a different light than the letter of intent alone. That would not automatically rebut every allegation in the lawsuits, but it would mark operational progress on precisely the conversion investors need to see. Conversely, delayed deliveries or a lack of new orders would weaken the cooperation's value as an investment argument.

The next fixed checkpoint is D-Wave's third-quarter 2026 report, scheduled for release before the market opens on November 10. That date gives investors the chance to set the application news alongside the financial development. The yardstick should be neither the daily share move nor the glow of individual technical wins, but a clean separation: what has been scientifically demonstrated, what is commercially intended, and what has actually been realized in economic terms. In a soft sector environment, that distinction only grows more important.